UBS analyst Danielle Antalffy lowered the firm’s price target on Edwards Lifesciences (EW) to $94 from $95 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Buy Rating Backed by Favorable TAVR Reimbursement Outlook and Asymptomatic Coverage Upside
- Edwards Lifesciences price target raised to $110 from $105 at Stifel
- Edwards Lifesciences price target raised to $98 from $95 at Piper Sandler
- Edwards Lifesciences price target raised to $95 from $92 at UBS
- Edwards Lifesciences price target raised to $90 from $87 at Baird